Search the Newsreel

Bitmine Immersion (BMNP) schedules 17 cash dividends on Series A preferred

Bitmine Immersion Technologies (BMNP) has announced that its Board of Directors declared seventeen cash dividends for its 9.50% Series A Perpetual Preferred Stock. These dividends will be paid in cash, with record dates spanning from August 25, 2026, through December 18, 2026, and corresponding …

Bitmine Announces New Round of Cash Dividends

Bitmine Immersion Technologies has declared 17 cash dividends on its 9.50% perpetual preferred stock, with payments scheduled from September through December 2026. This move, reflecting stable cash flow and a commitment to shareholders, is expected to boost investor confidence and potentially attract more institutional …

Deep Track reports 7.99M-share, 9.74% stake in MoonLake (MLTX) in 13G/A

Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have filed an amended Schedule 13G/A, reporting a collective beneficial ownership of 7,999,025 Class A ordinary shares, representing a 9.74% stake in MoonLake Immunotherapeutics (MLTX). This ownership includes 1,000,000 Pre-Funded Warrants, …

HC Wainwright Issues Negative Forecast for Immunome Earnings

Are Wall Street Analysts Bullish on Zimmer Biomet Stock?

Zimmer Biomet headquarters_By jetcityimage Zimmer Biomet Holdings, Inc. (ZBH), headquartered in Warsaw, Indiana, designs, manufactures, and sells medical equipment. Valued at $18.7 billion by market cap, the company offers orthopedic, dental, and spinal reconstructive implants, as well as bone cement and related surgical products. …

How Investors May Respond To Immunocore (IMCR) Turning First-Half Profit Amid Recent Share Price Pullback

Immunocore Holdings plc reported a significant improvement in its financial performance, achieving profitability in the first half of 2026 with net income of US$12.16 million, up from a loss the previous year. This positive shift is driven by increased revenue, though the company's investment …

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX

Pomerantz LLP is investigating potential securities fraud claims against Immix Biopharma, Inc. (IMMX) following a significant drop in its stock price. The investigation stems from the company's termination of its Chief Medical Officer, Richard Graydon, who was later identified by media outlets as Ronald …

Citizens reiterates Immix Biopharma stock rating on pipeline progress

Citizens reiterated a "Market Outperform" rating and a $23.00 price target for Immix Biopharma (NASDAQ:IMMX), citing strong pipeline progress and potential for significant upside despite recent financial losses and an "overvalued" assessment by InvestingPro. The firm highlighted upcoming top-line results for NXC-201 in September …

Sirenia Capital discloses 4.3% Immunome (IMNM) stake in Schedule 13G/A

Sirenia Capital Management LP and Alex Silverstein have reported a 4.3% beneficial ownership stake in Immunome Inc. (IMNM) through an amended Schedule 13G filing. They collectively hold 4,832,279 shares of common stock, representing 4.3% of the 113,250,394 shares outstanding as of May 7, 2026. …

5 Revealing Analyst Questions From Zimmer Biomet’s Q2 Earnings Call

5 Revealing Analyst Questions From Zimmer Biomet's Q2 Earnings Call Zimmer Biomet's second quarter results were driven by strong execution in its hip franchise, robust technology sales, and progress in the U.S. sales force transformation. CEO Ivan Tornos highlighted that new product adoption, such …

ImmuneOnco Sets August Board Meeting to Approve Interim Results and Mull Dividend

Handelsbanken Fonder AB Buys 28,130 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Handelsbanken Fonder AB increased its stake in Zimmer Biomet Holdings, Inc. by 22.7% in the second quarter, purchasing an additional 28,130 shares to bring its total to 152,064 shares valued at approximately $13.1 million. Zimmer Biomet exceeded Q2 earnings expectations with $2.07 EPS and …

BitMine Immersion Technologies (BMNR) 10K Form and Latest SEC Filings 2026

Altimmune (ALT) President and CEO Jerome Durso Buys 15,000 Shares

Altimmune Inc.'s President and CEO, Jerome Durso, recently purchased 15,000 shares of the company's stock, increasing his direct ownership to 62,500 shares. This transaction is part of a larger trend of insider buying at Altimmune, with 11 insider buys and no sells in the …

ImmuCell (NASDAQ:ICCC) Announces Earnings Results, Beats Estimates By $0.15 EPS

ImmuCell (NASDAQ:ICCC) reported its earnings results, beating the consensus estimate by $0.15 EPS with reported earnings of $0.20 per share. The biotechnology company also surpassed revenue expectations, bringing in $7.19 million against an anticipated $5.40 million. Despite these positive financial results, the company maintains …

Estrella Immunopharma, Inc. 2Q 2026: Net loss $(2.31M), EPS $(0.05) — 10-Q Summary

Estrella Immunopharma, Inc. reported a net loss of $(2.31M) for the second quarter of 2026, with a loss per share of $(0.05). The company remains pre-revenue, driven by ongoing development and corporate expenses. Key highlights include progress in clinical trials, significant milestones in a …

Zimmer Biomet (ZBH) sees Dodge & Cox disclose 12.5% ownership stake

Dodge & Cox has filed an amended Schedule 13G, revealing a 12.5% beneficial ownership stake in Zimmer Biomet Holdings, Inc. (ZBH), as of June 30, 2026. This represents 24,124,735 shares, with Dodge & Cox holding sole voting power over 22,808,935 shares and sole dispositive …

IMMUCELL CORP /DE/ Q2 2026: Revenue $7.19M, EPS $0.2— 10-Q Summary

IMMUCELL CORP /DE/ (ICCC) reported strong second-quarter 2026 results, with revenue reaching $7.19M and diluted EPS of $0.20, significantly up from the previous year. This growth was primarily driven by increased volumes and pricing for its First Defense product, which accounted for over 99% …

ImmuCell Plans About $4.5M Expansion for Calf Health Products

ImmuCell (NASDAQ: ICCC) reported strong Q2 2026 financial results with product sales up 11.5% to $7.2 million and net income rising to $1.8 million, aided by a $2 million legal settlement. The company announced a two-phase, approximately $8.0 million expansion of its First Defense® …

ImmuCell Corporation (ICCC) doubles profit on higher First Defense sales

ImmuCell Corporation reported robust financial results for the first half of 2026, with net income doubling to $3.8 million due to increased First Defense sales and a significant $2.0 million settlement. The company's product sales grew by 20.9% to $17.5 million, largely driven by …

Altimmune (ALT) CEO Jerome Durso purchases 15,000 shares at $2.95 each

Altimmune, Inc.'s President and CEO, Jerome Benedict Durso, purchased 15,000 shares of the company's common stock at $2.95 per share on August 13, 2026. This transaction, conducted in the open market or a private transaction, increased his direct holdings to 62,500 shares. The Form …

Janus Henderson Group (IMMX) discloses 9.78M-share beneficial stake in Immix Biopharma

Janus Henderson Group Ltd., through its investment adviser subsidiaries, has reported a beneficial ownership of 9,783,192 shares of Immix Biopharma, Inc. common stock, representing 14.0% of the class. These shares are held in client accounts, known as Managed Portfolios, where Janus Henderson's asset managers …

ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus

Altimmune (ALT) reported a narrower-than-expected loss of 12 cents per share in Q2 2026, beating the Zacks Consensus Estimate of 15 cents. The company, which currently has no marketed drugs, focused on advancing its lead candidate, pemvidutide, with ongoing clinical studies for MASH, AUD, …

AC Immune takes Parkinson's vaccine into US trials as Phase II data near

AC Immune SA's experimental alpha-synuclein vaccine, ACI-7104, has received US FDA clearance for its IND and Fast Track Designation for early-stage Parkinson's disease. This allows the vaccine to expand into US clinical development, as it approaches key Phase II data. Interim Phase II results …

Altimmune, Inc. Q2 2026: Revenue $0 EPS $(0.12) — 10-Q Summary

Altimmune, Inc. reported its second-quarter 2026 results, showing no revenue and a net loss of $(22.83M), with diluted loss per share at $(0.12). This represents an improvement in EPS compared to $(0.27) in Q2 2025. Key business highlights include the start of the PERFORMA …

Immunic (IMUX) sees Soleus Capital group disclose 4.9% beneficial stake

Soleus Capital Master Fund, L.P. and its related entities have disclosed a 4.9% beneficial ownership stake in Immunic, Inc. (IMUX), totaling 679,200 shares. This includes shares issuable from pre-funded and common warrants. The ownership is based on 13,644,467 shares outstanding as of July 31, …

Will Zimmer Biomet’s Upgraded 2026 Guidance and Buyback Shift Zimmer Biomet Holdings’ (ZBH) Narrative

Zimmer Biomet Holdings (ZBH) reported strong Q2 2026 results, including US$2,177 million in sales and US$198.3 million in net income, alongside completing a US$496.84 million share buyback. Management also raised full-year guidance due to robust performance in its hip and technology segments. This move …

IBRX Stock Extends 5-Day Losing Streak — Retail Traders Pin Hopes On ‘Incredibly Strong’ Anktiva Sales And Earnings Beat

MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Expected to Rise, HC Wainwright Analyst Says

Immunovant (IMVT) Q1 2027 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 8:00 a.m. ET CALL PARTICIPANTS Chief Executive Officer - Matthew GlineInvestor Relations - Stephanie Lee Griffin TAKEAWAYS Cash and Cash Equivalents -- $797.8 million as of June 30, 2026, which management stated provides …

Immuron Limited (NASDAQ: IMRN) highlights antibody platform and CEO talk at Emerging Growth Conference

Lyell Immunopharma, Inc. (NASDAQ:LYEL) Given Average Recommendation of "Moderate Buy" by Brokerages

Lyell Immunopharma (NASDAQ:LYEL) has received an average recommendation of "Moderate Buy" from nine brokerages, with an average 12-month price target of $42, significantly higher than its current trading price. Despite the positive analyst sentiment, the company remains unprofitable, reporting a quarterly loss of $1.92 …

Dimensional Fund Advisors LP Raises Stake in Altimmune, Inc. $ALT

Dimensional Fund Advisors LP significantly increased its stake in Altimmune, Inc. by 268.7% during the first quarter, acquiring an additional 762,223 shares to own a total of 1.05 million shares valued at $3.22 million. Other institutional investors also adjusted their positions in Altimmune, which …

Dimensional Fund Advisors LP Acquires Shares of 216,140 BitMine Immersion Technologies, Inc. $BMNR

Dimensional Fund Advisors LP has acquired 216,140 shares of BitMine Immersion Technologies (NYSE:BMNR) in the first quarter, totaling approximately $4.28 million. Other institutional investors also adjusted their holdings in BMNR, while analyst ratings remain mixed with a "Moderate Buy" consensus but recent target price …

What date does Immunic's (IMUX) report Earnings - Earnings Calendar & Announcement

Immersion Corporation: Revenue and Earnings Analysts Forecasts Revisions | IMMR | US4525211078